CN105636585B - 微粉化特考韦瑞一水化物的再水化 - Google Patents

微粉化特考韦瑞一水化物的再水化 Download PDF

Info

Publication number
CN105636585B
CN105636585B CN201480056338.7A CN201480056338A CN105636585B CN 105636585 B CN105636585 B CN 105636585B CN 201480056338 A CN201480056338 A CN 201480056338A CN 105636585 B CN105636585 B CN 105636585B
Authority
CN
China
Prior art keywords
particles
polymorph form
monohydrate
moisture
exposing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480056338.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN105636585A (zh
Inventor
山塔库马尔·R·亚瓦纳吉玛特
马修·雷韦斯
N·K·彼得·塞缪尔
史蒂文·普里贝
谭英
丹尼斯·E·赫鲁比
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xijia Technology Co
Original Assignee
Xijia Technology Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xijia Technology Co filed Critical Xijia Technology Co
Publication of CN105636585A publication Critical patent/CN105636585A/zh
Application granted granted Critical
Publication of CN105636585B publication Critical patent/CN105636585B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201480056338.7A 2013-11-19 2014-11-14 微粉化特考韦瑞一水化物的再水化 Active CN105636585B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361906119P 2013-11-19 2013-11-19
US61/906,119 2013-11-19
PCT/US2014/065674 WO2015077143A1 (en) 2013-11-19 2014-11-14 Rehydration of micronized tecovirimat monohydrate

Publications (2)

Publication Number Publication Date
CN105636585A CN105636585A (zh) 2016-06-01
CN105636585B true CN105636585B (zh) 2020-02-07

Family

ID=53180052

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480056338.7A Active CN105636585B (zh) 2013-11-19 2014-11-14 微粉化特考韦瑞一水化物的再水化

Country Status (8)

Country Link
US (2) US10406103B2 (enExample)
EP (1) EP3043793B1 (enExample)
JP (1) JP6594303B2 (enExample)
CN (1) CN105636585B (enExample)
AU (2) AU2014353235B2 (enExample)
CA (1) CA2930461C (enExample)
IL (2) IL244731B (enExample)
WO (1) WO2015077143A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020252284A1 (en) * 2019-06-13 2020-12-17 Imbucanna, Inc Compressible cannabinoid pharmaceutical composition

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012018810A9 (en) * 2010-08-05 2012-04-05 Siga Technologies, Inc. St-246 liquid formulations and methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10232113A1 (de) * 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
US7737168B2 (en) 2003-06-20 2010-06-15 Siga Technologies, Inc. Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
US7687641B2 (en) * 2003-06-20 2010-03-30 Siga Technologies, Inc. Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
UA97349C2 (uk) 2005-09-08 2012-02-10 Х. Луннбэк А/С Стійкі тверді склади сертиндолу
MX363189B (es) 2007-04-23 2019-03-14 Siga Tech Inc Productos químicos, composiciones y métodos para tratamiento y prevención de infecciones de virus orthopox y enfermedades asociadas.
CN101445478B (zh) 2008-08-22 2011-04-06 中国人民解放军军事医学科学院生物工程研究所 含一个结晶水的化合物st-246及其晶体与制备方法
JP2011041888A (ja) * 2009-08-20 2011-03-03 Nippon Soda Co Ltd ジェットミル粉砕条件の最適化方法
KR20150092354A (ko) * 2010-03-23 2015-08-12 시가 테크놀로지스, 인크. 다형체 형태 ｓｔ―２４６ 및 제조방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012018810A9 (en) * 2010-08-05 2012-04-05 Siga Technologies, Inc. St-246 liquid formulations and methods

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Pharmacokinetic Comparison of a Single Oral Dose of Polymorph Form I versus Form V Capsules of the Antiorthopoxvirus Compound ST-246 in Human Volunteers;Jarasvech Chinsangaram,et al;《Antimicrobial Agents and Chemotherapy》;20120423;第56卷(第7期);3582-3586 *

Also Published As

Publication number Publication date
CA2930461A1 (en) 2015-05-28
US20160235676A1 (en) 2016-08-18
IL282098B2 (en) 2023-05-01
AU2014353235A1 (en) 2016-04-21
CN105636585A (zh) 2016-06-01
AU2019208252A1 (en) 2019-08-15
US10716759B2 (en) 2020-07-21
EP3043793A1 (en) 2016-07-20
IL282098B1 (en) 2023-01-01
WO2015077143A1 (en) 2015-05-28
EP3043793B1 (en) 2021-01-06
AU2019208252B2 (en) 2020-03-19
IL282098A (en) 2021-05-31
IL244731B (en) 2021-05-31
US20190380966A1 (en) 2019-12-19
JP2016537318A (ja) 2016-12-01
AU2014353235B2 (en) 2019-05-09
IL244731A0 (en) 2016-04-21
EP3043793A4 (en) 2017-05-10
CA2930461C (en) 2022-08-16
US10406103B2 (en) 2019-09-10
JP6594303B2 (ja) 2019-10-23

Similar Documents

Publication Publication Date Title
US20080004452A1 (en) Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
CN104758281A (zh) 用于治疗和预防正痘病毒感染和相关疾病的化合物、组合物和方法
JP6018041B2 (ja) Ｓｔ−２４６の多形型および調製方法
US20140057925A1 (en) Amorphous form of vilazodone hydrochloride and process for its preparation
EP2192901A2 (en) Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
US20150283249A1 (en) Amorphous form of apremilast
US20130345278A1 (en) Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
WO2009084023A2 (en) Amorphous ramelteon and process for the preparation thereof
CN105636585B (zh) 微粉化特考韦瑞一水化物的再水化
US9469673B2 (en) Crystaline forms of HCV inhibitor
JP6843616B2 (ja) アモルファステコビリマット調製
AU2012268859B2 (en) Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
EP3448854A1 (en) Crystalline polymorphs of ombitasvir
AU2016208315A1 (en) Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant